Top

Published in:

01-07-2006 | Original Article

Elemene displays anti-cancer ability on laryngeal cancer cells in vitro and in vivo

Authors: Lei Tao, Liang Zhou, Luying Zheng, Min Yao

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2006

Abstract

Purpose: The goal of this study is to investigate the inhibitory effects and mechanism of elemene on the growth of laryngeal cancer cells in vitro and in vivo. Methods: Laryngeal cancer cells (HEp-2 cells) were grown in elemene, cisplatin, or a combination of the drugs. The cytotoxic, or apoptotic, effects of elemene on the cells were evaluated by a 3-[4,5-dimethylthiazol-2yl]-2,5-diphenyltetrazolium bromide assay, flow cytometry, and a caspase-3 activity assay. A Western blot was used to semi-quantify the protein expression of eukaryotic initiation factors (eIF4E and eIF4G), basic fibroblast growth factor (bFGF), and vascular endothelial growth factor (VEGF); RT-PCR analysis semi-quantified the mRNA transcript expression of bFGF and VEGF. The HEp-2 cells were transplanted subcutaneously to BALB/c nude mice to produce solid tumors. Elemene and cisplatin were administered to the mice either as individual drugs or in combination. The tumors were excised and immunostained to determine the effect each drug had on tumor size, eIF levels, angiogenic factors, and microvessel density (MVD). Results: Elemene inhibited the growth of HEp-2 cells in vitro in a dose- and time-dependent manner with an IC₅₀ of 346.5 μM (24 h incubation). Increased apoptosis was observed in elemene-administered cells. Elemene is suspected to enhance caspase-3 activity, and thus inhibit protein expression of eIFs (4E, 4G), bFGF, and VEGF. In vivo, the growth of HEp-2 cell-transplanted tumors in nude mice was inhibited by intraperitoneal injection of elemene. Compared with control groups, elemene significantly inhibited the protein expression of eIFs (4E and 4G), bFGF, and VEGF and decreased the MVD. Conclusions: Elemene inhibits the growth of HEp-2 cells in vitro and in vivo. These data provide useful information for further clinical study on the treatment of LSCC by elemene.

Colasanto JM, Haffty BG, Wilson LD (2004) Evaluation of local recurrence and second malignancy in patients with T1 and T2 squamous cell carcinoma of the larynx. Cancer J 10:61–66PubMedCrossRef

Moyer JS, Wolf GT, Bradford CR (2004) Current thoughts on the role of chemotherapy and radiation in advanced head and neck cancer. Curr Opin Otolaryngol Head Neck Surg 12:82–87PubMedCrossRef

Weise JB, Maune S, Gorogh T, Kabelitz D, Arnold N, Pfisterer J, Hilpert F, Heiser A (2004) A dendritic cell based hybrid cell vaccine generated by electrofusion for immunotherapy strategies in HNSCC. Auris Nasus Larynx 31:149–153PubMedCrossRef

Kroep JR, Peters GJ, van Moorsel CJ, Catik A, Vermorken JB, Pinedo HM, van Groeningen CJ (1999) Gemcitabine-cisplatin: a schedule finding study. Ann Oncol 10:1503–1510PubMedCrossRef

Hitt R, Jimeno A, Millan JM, Castellano D, Cortes-Funes H (2004) Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck. Cancer 101:768–775PubMedCrossRef

Zheng S, Yang H, Zhang S, Wang X, Yu L, Lu J, Li J (1998) Initial study on naturally occurring products from traditional Chinese herbs and vegetables for chemoprevention. J Cell Biochem 67:106–112CrossRef

Chen SL, You J, Wang GJ (2001) Supercritical fluid extraction of beta-elemene under lower pressure. Se Pu 19:179–181PubMed

Zheng S, Yang H, Zhang S, Wang X, Yu L, Lu J, Li J (1997) Initial study on naturally occurring products from traditional Chinese herbs and vegetables for chemoprevention. J Cell Biochem Suppl 27:106–112PubMedCrossRef

Yang H, Wang X, Yu L (1996) The antitumor activity of elemene is associated with apoptosis. Zhonghua Zhong Liu Za Zhi 18:169–172PubMed

10.

Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, Newmeyer DD, Wang HG, Reed JC, Nicholson DW, Alnemri ES, Green DR, Martin SJ (1999) Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J Cell Biol 144:281–292PubMedCrossRef

11.

Yang XH, Sladek TL, Liu X, Butler BR, Froelich CJ, Thor AD (2001) Reconstitution of caspase-3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis. Cancer Res 61:348–354PubMed

12.

Gupta S (2001) Molecular steps of death receptor and mitochondrial pathways of apoptosis. Life Sci 69:2957–2964PubMedCrossRef

13.

Clemens MJ, Bushell M, Jeffrey IW, Pain VM, Morley SJ (2000) Translation initiation factor modifications and the regulation of protein synthesis in apoptotic cells. Cell Death Differ 7:603–615PubMedCrossRef

14.

De Benedetti A, Harris AL (1999) eIF4E expression in tumors: its possible role in progression of malignancies. Int J Biochem Cell Bio 31:59–72CrossRef

15.

Fukuchi-Shimogori T, Ishii I, Kashiwagi K, Mashiba H, Ekimoto H, Igarashi K (1997) Malignant transformation by overproduction of translation initiation factor eIF4G. Cancer Res 57:5041–5044PubMed

16.

McKendrick L, Pain VM, Morley SJ. Translation initiation factor 4E (1999) Int J Biochem Cell Bio 31:31–35CrossRef

17.

Zhang K, Chew M, Yang EB, Wong KP, Mack P (2001) Modulation of cisplatin cytotoxicity and cisplatin-induced DNA interstrand cross-links by regulation of glutathione related mechanisms. Mol Pharmacol 59:837–843PubMed

18.

Evens AM, Prachand S, Shi B, Paniaqua M, Gordon LI, Gartenhaus RB (2004) Imexon-induced apoptosis in multiple myeloma tumor cells is caspase-8 dependent. Clin Cancer Res 10:1481–1491PubMedCrossRef

19.

Muzio M, Salvesen GS, Dixit VM (1997) FLICE induced apoptosis in a cell-free system. Cleavage of caspase zymogens. J Biol Chem 272:2952–2956PubMedCrossRef

20.

Zhou L, Tao L, Zheng LY, Gao YP (2003) The expression of proto-oncogene eIF4E in laryngeal squamous cell carcinoma. Laryngoscope 113:1238–1243CrossRef

21.

Nanda GS, Sun FX, Hofmann GA, Hoffman RM, Dev SB (1998) Electroporation therapy of human larynx tumors HEp-2 implanted in nude mice. Anticancer Res 18:999–1004PubMed

22.

Zhang K, Chow PK (2004) The effect of megestrol acetate on growth of HepG2 cells in vitro and in vivo. Clin Cancer Res 10:5226–5232PubMedCrossRef

23.

Pavelic Z, Pavelic K, Cater C, Pavelic L (1992) Heterogeneity of c-myc expression in histologically similar infiltrating ductal carcinomas of the breast. J Cancer Res Clin Oncol 118:16–22PubMedCrossRef

24.

Gong W, Wang L, Yao JC, Ajani JA, Wei D, Aldape KD, Xie K, Sawaya R, Huang S (2005) Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin Cancer Res 11:1386–1393PubMedCrossRef

25.

Baskota DK, Prasad R, Sinha BK, Amatya RC, Bhattarai H, Guragain RP (2004) Outcome of surgical management of laryngeal carcinoma: a 5-year experience. Acta Otolaryngol 124:739–743PubMedCrossRef

26.

Jazirehi AR, Bonavida B (2005) Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin’s lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 24:2121–2143PubMedCrossRef

27.

Movsas B, Scott C, Langer C, Werner-Wasik M, Nicolaou N, Komaki R, Machtay M, Smith C, Axelrod R, Sarna L, Wasserman T, Byhardt R (2005) Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. J Clin Oncol 23:2145–2154PubMedCrossRef

28.

Douer D, Tallman MS (2005) Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol 23:2396–2410PubMedCrossRef

29.

Hu J, Jin W, Yang PM (2004) Reversal of resistance to adriamycin in human breast cancer cell line MCF-7/ADM by beta-elemene. Zhonghua Zhong Liu Za Zhi 26:268–270PubMed

30.

Zhou HY, Shen JK, Hou JS, Qiu YM, Luo QZ (2003) Experimental study on apoptosis induced by elemene in glioma cells. Ai Zheng 22:959–963PubMed

31.

Bier H, Bergler W, Mickisch G, Wesch H, Ganzer U (1990) Establishment and characterization of cisplatin-resistant sublines of the human squamous carcinoma cell line HLac 79. Acta Otolaryngol 110:466–473PubMed

32.

Engbers-Buijtenhuijs P, Kamphuis M, van der Sluijs Veer G, Haanen C, Poot AA, Feijen J, Vermes I (2005) A novel time resolved fluorometric assay of anoikis using Europium-labelled Annexin V in cultured adherent cells. Apoptosis 10:429–437PubMedCrossRef

33.

Pulkkinen JO, Elomaa L, Joensuu H, Martikainen P, Servomaa K, Grenman R (1996) Paclitaxel-induced apoptotic changes followed by time-lapse video microscopy in cell lines established from head and neck cancer. J Cancer Res Clin Oncol 122:214–218PubMedCrossRef

34.

Fujita E, Egashira J, Urase K, Kuitda K, Momoi T (2001) Caspase-9 processing by caspase-3 via a feedback amplification loop in vivo. Cell Death Differ 8:335–344PubMedCrossRef

35.

Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA (2002) Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376:37–43CrossRef

36.

Wang X, Zelenski NG, Yang J, Sakai J, Brown MS, Goldstein JL (1996) Cleavage of sterol regulatory element binding proteins (SREBPs) by CPP32 during apoptosis. EMBO J 15:1012–1020PubMed

37.

Liu B, Hannun YA (1997) Inhibition of the neutral magnesium-dependent sphingomyelinase by glutathione. J Biol Chem 272:16281–16287PubMedCrossRef

38.

Casciola-Rosen L, Nicholson DW, Chong T, Rowan KR, Thornberry NA, Miller DK, Rosen A (1996) Apopain/CPP32 cleaves proteins that are essential for cellular repair: a fundamental principal of apoptotic death. J Exp Med 183:1957–1964PubMedCrossRef

39.

Liu L, Simon MC (2004) Regulation of transcription and translation by hypoxia. Cancer Biol Ther 3:492–427PubMed

40.

von Der Haar T, Ball PD, McCarthy JE (2000) Stabilization of eukaryotic initiation factor 4E binding to the mRNA 5’-Cap by domains of eIF4G. J Biol Chem 275:30551–30555CrossRef

41.

Scheper GC, Proud CG (2002) Does phosphorylation of the cap-binding protein eIF4E play a role in translation initiation? Eur J Biochem 269:5350–5359PubMedCrossRef

42.

Prevot D, Darlix JL, Ohlmann T (2003) Conducting the initiation of protein synthesis: the role of eIF4G. Biol Cell 95:141–156PubMedCrossRef

43.

Tee AR, Proud CG (2002) Caspase cleavage of initiation factor 4E-binding protein 1 yields a dominant inhibitor of cap-dependent translation and reveals a novel regulatory motif. Mol Cell Biol 22:1674–1683PubMedCrossRef

44.

Bushell M, McKendrick L, Janicke RU, Clemens MJ, Morley SJ (1999) Caspase-3 is necessary and sufficient for cleavage of protein synthesis eukaryotic initiation factor 4G during apoptosis. FEBS Lett 451:332–336PubMedCrossRef

45.

Sivan HK, Naomi LS, Dan G, Adi K (2000) A novel form of DAP5 protein accumulates in apoptotic cells as a result of caspase cleavage and internal ribosome entry site-mediated translation. Mol Cell Biol 20:496–506CrossRef

46.

Brown LF, Guidi AJ, Schnitt SJ, Van De Water L, Iruela-Arispe ML, Yeo TK, Tognazzi K, Dvorak HF (1999) Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res 5:1041–1056PubMed

47.

Lund EL, Thorsen C, Pedersen MW, Junker N, Kristjansen PE (2000) Relationship between vessel density and expression of vascular endothelial growth factor and basic fibroblast growth factor in small cell lung cancer in vivo and in vitro. Clin Cancer Res 6:4287–4291PubMed

48.

Pignataro L, Carboni N, Midolo V, Bertolini F, Buffa R, Cesana BM, Neri A, Viale G, Pruneri G (2001) Clinical relevance of microvessel density in laryngeal squamous cell carcinomas. Int J Cancer 92:666–670PubMedCrossRef

49.

Bruns CJ, Liu W, Davis DW, Shaheen RM, McConkey DJ, Wilson MR, Bucana CD, Hicklin DJ, Ellis LM (2000) Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer 89:488–499PubMedCrossRef

Title: Elemene displays anti-cancer ability on laryngeal cancer cells in vitro and in vivo
Authors: Lei Tao
Liang Zhou
Luying Zheng
Min Yao
Publication date: 01-07-2006
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 1/2006
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-005-0137-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2006

Enforced expression of cytosolic 5′-nucleotidase I confers resistance to nucleoside analogues in vitro but systemic chemotherapy toxicity precludes in vivo selection

Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors

Human breast cell lines exhibit functional α2-adrenoceptors

p53 Status does not affect photodynamic cell killing induced by hypericin

Chemoprotection effect of retroviral vector encoding multidrug resistance 1 gene to allow intensified chemotherapy in vivo

Dibenzocyclooctadiene lingnans: a class of novel inhibitors of P-glycoprotein

Keynote webinar | Spotlight on antibody–drug conjugates in cancer